Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spry2 expression correlates with BRAF mutation in thyroid cancer.

Surgery - 1 Dec 2010

Xu Lizhong, Zhou Jun Liang, Cohen Michael, Bar-Sagi Dafna, Patel Kepal N

Abstract excerpt

BACKGROUND: BRAF mutations activate the mitogen-activated protein kinase pathway and often confer an aggressive thyroid cancer (TC) phenotype. Spry2 is an inducible negative feedback regulator of the mitogen-activated protein kinase (MAPK) pathway. The aim of this study was to investigate the role of Spry2 in TC. METHODS: TC cell lines were analyzed for Spry2 expression and MAPK pathway activation. Cells were...

Topics

Join the communities discussing this publication.

Cell Line, Tumor
Culture Media
Intracellular Signaling Peptides and Proteins
Proto-Oncogene Proteins B-raf
RNA Interference

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

RNA, Small Interfering

Thyroid Neoplasms

Source

Identifiers

PMID: 21134562
DOI: 10.1016/j.surg.2010.09.028

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spry2 expression correlates with BRAF mutation in thyroid cancer.PMID 21134562Read ↗

Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.Semantic proximity Read ↗

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Semantic proximity Read ↗

Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.Semantic proximity Read ↗

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.Semantic proximity Read ↗

Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer.Semantic proximity Read ↗

PD-1 Blockade Delays Tumor Growth by Inhibiting an Intrinsic SHP2/Ras/MAPK Signalling in Thyroid Cancer CellsSemantic proximity Read ↗

SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibitionSemantic proximity Read ↗

ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.Semantic proximity Read ↗

Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Semantic proximity Read ↗

DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.Semantic proximity Read ↗

BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell LinesSemantic proximity Read ↗

Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.